Loading Events

« All Events

  • This event has passed.

Psychopharmacology Update 2019

November 9, 2019 @ 8:30 am - 4:30 pm



About The Program:

Please join us for the Maryland Psychiatric Society’s Annual Psychopharmacology Update in Baltimore! All of our dynamic sessions will be presented by a slate of distinguished faculty on a wide variety of topics tailored towards psychiatrists and mental health clinicians who need the most up-to-date information available. The course is meant for all clinicians who prescribe psychotropic medications, and will address indications, contraindications, management of adverse events and more. It includes a focus on complex and challenging conditions, atypical presentations and special populations throughout the life cycle.


9:00-10:00       Esketamine for Treatment Resistant Depression: How Special is Special K:Evolution, Revolution or Fashion?– Adam Kaplin, MD, PhD

10:00-11:00    Brexanolone: Clinical Considerations and Future Research Directions – Lindsay Standeven, MD

11:00-11:15     BREAK

11:15-12:15     The Past and Future of Vagus Nerve Stimulation for Treatment Resistant Depression Scott Aaronson, MD

12:15-1:15       LUNCH

1:15-2:15         Psilocybin Treatment of Depression and Tobacco Addiction- Matt Johnson, Ph.D.

2:15-3:15         Optimizing Psychiatric Treatment Regimens to Treat Pain – Liz Prince, DO

3:15-3:30         BREAK

3:30-4:30         Deep TMS for OCD – Geoff Grammer, MD


About The Speakers:

Scott Aaronson, MD – is the director of clinical research at Sheppard Pratt. He has particularly been involved with the development of new strategies to alleviate the symptoms in treatment resistant mood disorders, and has published numerous articles  on pivotal studies in the use of devices—Transcranial Magnetic Stimulation (TMS) and Vagus Nerve Stimulation (VNS) in the treatment of severe refractory mood disorders.

Geoff Grammer, MD – is an Assistant Professor of Psychiatry at the Uniformed Services University. He serves as Greenbrook TMS NeuroHealth’s Chief Medical Officer, the largest TMS provider in the United States with over 80 centers.  Dr. Grammer created one of the very first TMS Therapy centers in the United States and is valued as a leading practitioner of TMS Therapy by his colleagues.

Matt Johnson, Ph.D. – is an Associate Professor of Psychiatry and Behavioral Sciences at Johns Hopkins Hospital. His research interests include human behavior change, especially in the context of addiction recovery. His expertise is in addiction medicine, drug abuse research and drug dependence

Adam Kaplin, MD, PhD – is an Assistant Professor of Neurology & Psychiatry and Behavioral Sciences at Johns Hopkins Hospital. He is the Chief Psychiatric Consultant for the Johns Hopkins MS Center and his areas of expertise include Neuropsychiatry, Mental Health Information Technology and Psychoneuroimmunology.

Liz Prince, DO – is an Instructor of Psychiatry at Johns Hopkins University. Following medical school at the Touro College of Osteopathic Medicine in New York City, Dr. Prince completed her internship and residency in psychiatry at Johns Hopkins. She went on to a fellowship in consultation-liaison psychiatry at University of Maryland Medical Center before returning to join the faculty at Johns Hopkins.

Lindsay Standeven, MD – is in her last year of fellowship training in Reproductive Psychiatry in the Department of Psychiatry and Behavioral Science at Johns Hopkins. She is certified by the American Board of Psychiatry And Neurology and completed her residency at Johns Hopkins University School of Medicine.



At the end of this educational activity, the learner will be able to:

  • Describe the features of a treatment resistant depression (TRD)
  • Identify potential candidates most likely to benefit from vagus nerve stimulation (VNS) for depression
  • Differentiate between scales rating severity of depression from scales evaluating quality of life and how each should impact on clinical decision making.
  • Describe differences in magnetic field generations with different TMS coil types
  • Name areas of the brain implicated in OCD and affected by deep TMS
  • Define outcomes in the deep TMS for OCD clinical trial that was considered in FDA approval
  • Identify disorders which are being investigator regarding treatment with psilocybin
  • Identify risks of administering psilocybin
  • Describe safety mechanisms for mitigating risks in psilocybin research
  • Learn the risks, benefits and alternatives to the use of esketamine for treatment resistant depression.
  • Understand the presumed basic mechanism of action of low dose esketamine and why that results in unique clinical characteristics of this novel, recently approved antidepressant therapy
  • Describe to patients the basis for the approval by the FDA of this treatment, and what the risks are and side effects, as well as unique clinical applications
  • Identify the somatic and psychiatric relative contraindications to the use of esketamine
  • Discuss the epidemiology of perinatal depression and anxiety
  • Understand of biological background that fueled interest in Brexanalone
  • Review scientific literature on Brexanalone and strength of findings
  • List clinical challenges in Brexanalone administration
  • Understand how pain and psychiatric illness are related
  • Discuss how pain medications relate to psychiatric illness
  • Identify psychiatric treatments that can impact pain
  • Review management strategies for patients with psychiatric illness and pain disorders

Accreditation/Designation Information

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of American Psychiatric Association (APA) and Maryland Psychiatric Society (MPS).   The APA is accredited by the ACCME to provide continuing medical education for physicians.  The APA designates this live activity for a maximum of 6 AMA PRA Category 1 Credit(s) TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is approved for a maximum of 6 hours of Category I Continuing Education for Social Workers by the Maryland Board of Social Workers.

This activity is approved for a maximum of 6 hours of Continuing Education for Psychologists by the Maryland Board of Examiners for Psychologists.












November 9, 2019
8:30 am - 4:30 pm


Maryland Psychiatric Society


Conference Center at Sheppard Pratt
6501 North Charles Street
Towson, MD 21204 United States
+ Google Map

The Maryland Psychiatric Society, Inc. District Branch of the American Psychiatric Association
1101 Saint Paul Street, Suite 305 Baltimore, Maryland 21202-6407

Privacy Notice | Phone: (410) 625-0232 / Fax: (410) 625-0277

© 2020 The Maryland Psychiatric Society, Inc. All Rights Reserved. Web Design & Marketing by G.1440